Operator
Operator
Good morning and welcome to the Chart Industries Incorporated 2015 Second Quarter Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. As a reminder, today's call is being recorded. You should have already received the company's earnings release that was issued earlier this morning. If you have not received the release, you may access it by visiting Chart's web site at www.chartindustries.com. A telephone replay of today's broadcast will be available following the conclusion of the call until Thursday, August 6. The replay information is contained in the company's earnings release. Before we begin, the company would like to remind you that statements made during this call that are not historical in fact are forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied in the forward-looking statements. For further information about important factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, please refer to the information regarding forward-looking statements and risk factors included in the company's earnings release and latest filings with the SEC. These filings are available through the Investor Relations section of the company's web site or through the SEC web site, www.sec.gov. The company undertakes no obligation to update publicly or revise any forward-looking statements. I would now like to turn the conference call over to Michael Biehl, Chart Industries' Executive Vice President and CFO. You may begin your conference. Michael F. Biehl - Executive Vice President & Chief Financial Officer: Thank you, Kath. Good morning, everyone. I'd like to thank you all for joining us today. Begin by giving you a brief overview of our second quarter results, and then Sam Thomas will provide comments on current market and order trends we see in each of our business segments. I'll then finish up by commenting on our outlook for the remainder of 2015. Net income for the second quarter of 2015 was $17.2 million or $0.56 per diluted share. This include the Owatonna, Minnesota facility shutdown and other severance costs recorded in the quarter of approximately $1.7 million or $0.04 per diluted share. Excluding these items, second quarter 2015 earnings would have been $0.60 per diluted share. This compares with net income of $20.1 million or $0.65 per diluted share for the second quarter of 2014. Second quarter 2014 earnings would have been $0.70 per share excluding the $0.05 per diluted share impact of the acquisition-related costs and dilution impact associated with the Chart's convertible notes during that period. We also had a foreign currency transaction gain of $3.1 million for the second quarter of 2015, or $0.07 per diluted share, given the volatility in currency rates. This effectively offset the $0.07 per diluted share loss we had in the first quarter of 2015. Sales for the quarter were $270.3 million, a 12% decline from the prior year quarter. This was largely due to decline in LNG sales in our D&S business, particularly in China. But currency translation had an unfavorable impact as well. Translation effect from the strong dollar reduced consolidated sales about $9 million and gross profit by about $2.3 million in the second quarter of 2015 on a constant currency basis. Our gross profit for the quarter was $74.9 million or 27.7% of sales, compared with $92.2 million or 30% of sales a year ago. Overall, gross profit was down due to lower sales volume and higher restructuring related costs in our D&S business. This was partially offset by previously announced cost reductions, in addition to improved project mix and execution in our E&C business. Orders received in the second quarter totaled $231.1 million and were up sequentially from first quarter 2015. Net orders and backlogs were however reduced in the second quarter 2015 by $47.6 million to address adjustments in the D&S Asia backlog for customers in China that are not able to confirm delivery and previously committed orders, primarily due to the impact of lower oil prices and the overall economic slowdown in China. As a result, reported orders for the second quarter of 2015 were $183.5 million, net of the $47.6 million backlog adjustment in China. In the E&C business, sales decreased 1.7% to $91.3 million for second quarter of 2015. The decline was due to lower sales volume in brazed aluminum heat exchangers, which was partially offset by improved project mix in process systems. Gross margins were 30.3% in the quarter, compared with 26.5% in the prior year quarter. The negative margin impact of lower brazed aluminum heat exchanger volume was more than offset by improved project mix and execution, in addition to the absence of start-up costs related to the La Crosse expansion and Wuxi acquisition in the prior year quarter. In our D&S business, second quarter sales decreased 18.3% year-over-year to $121.8 million. The impact of lower global oil prices and a weak economic environment in China is negatively impacting our D&S Asia business. Sales volumes are down 35% in the current quarter over the prior year quarter in China. In addition, the currency translation impact in our D&S European business reduced sales by approximately $6 million on a constant currency basis. D&S gross margins were 23.4% compared with 30.6% in the prior year quarter. Lower LNG volume, restructuring and costs associated with the Owatonna shutdown, and other cost reduction initiatives, as well as product mix led to decline. In addition, the prior year quarter included the favorable resolution of a partial contract cancellation from a major oil company customer, which improved D&S margins about 1.5%. In BioMedical, sales decreased 11.8% year-over-year to $57.1 million. The decline is primarily due to lower respiratory sales volume in Europe due to delays in the tendering process and currency impact due to the strength of the U.S. dollar. The currency translation impacting in our BioMedical business reduced sales by approximately $3 million on a constant currency basis. BioMedical gross profit margin declined to 32.8% in the quarter compared with 33.8% for the same period of 2014, due to lower volume and product mix. SG&A expense for the quarter was $45.6 million, down $8 million compared with the same quarter a year ago. The decrease was largely due to lower variable base incentive compensation based on current performance, lower bad debt expense due to improved collections on some old outstanding balances, and favorable impact from cost reductions initiated in the fourth quarter of last year. Income tax expense was $6.9 million for the second quarter and represented an effective tax rate of 28.7% compared with $8.8 million for the prior year's second quarter, which was an effective tax rate of 30.2%. The decrease in the effective tax rate was primarily due to the effect of income earned by certain of the company's foreign entities, which are taxed at lower rates. I'll now turn the call over to Sam Thomas. Samuel F. Thomas - Chairman, President & Chief Executive Officer: Thank you, Michael, and good morning everyone. Our second quarter results again reflect solid performance across many of our businesses despite the uncertainty in global oil pricing, which continues to cause customers in the energy space to defer investment decisions. We continue to focus on our core business with disciplined execution, strong management involvement and aggressive cost cutting. While remaining circumspect with regard to the impact of uncertainty in oil pricing, we're encouraged by the growing interest and activity in North American LNG export facilities, and specifically the move towards multi-train mid-scale liquefaction. The pending order we included in the earnings release today for brazed aluminum heat exchangers, Core-in-Kettle exchangers, and Cold boxes for the four-train Magnolia LNG project, which will incorporate Magnolia's OSMR technology is one of a number of projects we have been pursuing in this space. We expect a staged release of Magnolia commencing in the third quarter with a commitment for all four trains by the end of 2015. The total order value is expected to be in excess of $80 million. Venture Global LNG and Parallax Energy's Live Oak LNG and Mississippi LNG projects, which I've mentioned on previous calls and which we are currently performing advanced engineering for, fall into the same multi-train mid-scale category. However, these projects will employ Chart's own IPSMR liquefaction process and would be significantly larger in scope for Chart. Low oil prices and significant economic malaise in China remain one of our largest challenges. We do expect demand to recover as the government continues to support its pollution control goals, however, we do not expect a significant 2015 improvement. We've had disappointing sales, orders and order prospects, despite the optimism within China and our customer base the recovery is just around the corner. We are aggressively addressing that disconnect with appropriate cost reductions. Overall, as I commented last quarter, 2000 (sic) [2015] is proving to be a challenging year. Earlier optimism regarding recovery of oil prices and China activity in the second half of 2015 now appear unfounded. We still expect to see growth in our D&S packaged gas and BioMedical markets, but we face a continued deterioration in prospects in D&S LNG applications based on diesel fuel replacement, especially in China. We also faced similar challenges within E&C for petrochemical, natural gas processing and industrial gas prospects as the energy industry has pulled back on capital spending. Global competition continues to put pressure on pricing. In response, we continue to focus on our cost reduction initiatives as evidenced by our performance this quarter. Since we began our cost cutting efforts in the fourth quarter of 2014, our head count reduction now stands at 12% of our global workforce. These head count reductions and other actions equate to annualized savings in excess of $40 million. I would again like to emphasize that despite the current headwinds we're facing, we remain confident that our focus on meeting and exceeding customer needs and the long-term fundamental drivers of growth, including rising industrial production and increased global demand for energy, natural gas in particular, and the growing need for respiratory healthcare, particularly in developing countries, will deliver results. We are continuing to invest for future growth, including pursuing potential acquisition candidates. The acquisition of vaporizer manufacturer, Thermax, which we completed in July, is validation of our growth intentions. Let me now comment on specific highlights for each of our businesses. Within Energy and Chemicals, we booked $23 million in orders during the second quarter. This is down sequentially from first quarter 2015 orders of $43 million. As I alluded to earlier, while we are certainly experiencing deteriorating short-term prospects and pricing pressure, most notably for brazed aluminum heat exchangers, the timing of project awards is historically lumpy in the E&C segment and always a challenge to forecast. As I mentioned earlier, we are encouraged by the continued interest in quoting activity for mid-scale multi-train liquefaction for LNG export facilities here in North America, which is to be largely unaffected by current oil prices. The Magnolia LNG project is a good example of this and we are cautiously optimistic that equipment orders will be forthcoming for other LNG export projects over the next year, some of which could be much larger than that currently announced. Within Distribution & Storage, we booked orders of $149.6 million in the second quarter, an increase of 21% from our first quarter 2015 orders of $124 million, led by particularly strong orders in the U.S. The adjustments Michael mentioned in our China backlog reduced reported quarterly orders, of course, as we report them on a net basis. Global industrial gas activity remains in line with expectations, despite reduced volumes reported by many of our large customers, and is still expected to grow marginally in 2015, based on rising industrial production and major customer forecasts. Our D&S U.S. orders were the strongest since the first quarter of 2012 and included a broad range of orders for both industrial gas and LNG related opportunities. Although LNG orders within D&S remain weak globally, opportunities still exist. We did see LNG orders in the U.S. related to LNG vehicle tanks with Scania and an LNG Storage and Regasification system for a mine project in Canada. We continue to quote significant opportunities for LNG distribution equipment; that could result in orders later this year or 2016. This includes ISO containers for transport on railcars and ships, in addition to other equipment used in the LNG virtual pipeline. Moving on to BioMedical, orders of $59 million were up 11% compared to the first quarter of 2015. Order intake for both life sciences and respiratory healthcare was up from the prior quarter. Orders for commercial oxygen systems were down marginally from the prior quarter and somewhat lower than expected due to project timing, which again is historically lumpy for the second quarter. Second quarter 2015 performance substantiated our belief that respiratory healthcare has stabilized and it is now more predictable. As we reported last quarter, we still expect to see modest growth in the respiratory healthcare business in the second half of 2015. Finally, we remain confident that our life sciences and commercial oxygen system businesses will both show growth as we move through 2015. Michael will now provide our outlook for the remainder of 2015. Michael F. Biehl - Executive Vice President & Chief Financial Officer: Thanks, Sam. The pending Magnolia LNG order will not have a major impact on 2015 operating results, given the long lead time nature of the project. Given the first half and forecasted order trends, factored in backlog reductions, the continued decline in the economic environment, particularly in China, in addition to the recent decline in oil prices, we are lowering our 2015 guidance range. We expect sales for 2015 to now be in the range of $1.0 billion to $1.1 billion, diluted earnings per share to be in the range of $1.40 to $1.60 per diluted share on approximately 30.7 million weighted shares outstanding. This excludes the impact of any restructuring related costs from our cost reduction initiatives. We do expect at least another $3 million in restructuring related cost at this time in the second half of this year, which includes approximately $2 million for lease termination costs with the Owatonna, Minnesota facility and $1 million for additional severance associated with our cost reduction initiatives which is not reflected in our revised earnings forecast. I'd now like to open it up for questions. Kath, please provide instructions to the participants to be able to ask questions.